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Abstract 
Microneedle devices have been proposed as a minimally invasive delivery system for 
the intradermal administration of nucleic acids, both plasmid DNA (pDNA) and 
siRNA, to treat localised disease or provide vaccination. Different microneedle types 
and application methods have been investigated in the laboratory, but limited and 
irreproducible levels of gene expression have proven to be significant challenges to 
pre-clinical to clinical progression. This study is the first to explore the potential of a 
hollow microneedle device for the delivery and subsequent expression of pDNA in 
human skin. The regulatory approved MicronJet600® (MicronJet hereafter) device 
was used to deliver reporter plasmids (pCMVβ and pEGFP-N1) into viable excised 
human skin. Exogenous gene expression was subsequently detected at multiple 
locations that were distant from the injection site but within the confines of the bleb 
created by the intradermal bolus. The observed levels of gene expression in the 
tissue are at least comparable to that achieved by the most invasive microneedle 
application methods e.g. lateral application of a microneedle. Gene expression was 
predominantly located in the epidermis, although also evident in the papillary dermis. 
Optical coherence tomography permitted real time visualisation of the sub-surface 
skin architecture and, unlike a conventional intradermal injection, MicronJet 
administration of a 50μl bolus appears to create multiple superficial microdisruptions 
in the papillary dermis and epidermis. These were co-localised with expression of the 
pCMVβ reporter plasmid. We have therefore shown, for the first time, that a hollow 
microneedle device can facilitate efficient and reproducible gene expression of 
exogenous naked pDNA in human skin using volumes that are considered to be 
standard for intradermal administration, and postulate a hydrodynamic effect as the 
mechanism of gene delivery. 
 
Keywords: Microneedles, human skin, DNA, genetic vaccine, gene therapy, 
hydrodynamic 
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1. Introduction 
Intradermal delivery of plasmid DNA (pDNA) has been proposed for a number of 
therapeutic applications (Abdul-Wahab et al. 2014, Hart and Vile, 1994), including 
DNA vaccines, which are targeted to the skin to exploit the highly evolved and 
competent local immune system (Robinson, 1999, Kutzler and Weiner, 2008). 
However, although detectable expression of exogenous genes in human and animal 
skin was achieved over 20 years ago (Hengge et al. 1995, Hengge et al. 1996, 
Hengge et al. 1998, Yu et al. 1999), clinical translation has been hindered by extra- 
and intra-cellular barriers to efficient and reproducible cell transfection.  
 
Cell barriers to transfection have been well characterised in numerous cell types, 
including skin cells. Viral vectors enable efficient and long-term expression of 
exogenous genes (Howarth et al. 2010) but they have a number of acknowleged 
constraints (Boulaiz et al. 2005, Lv et al. 2006, Mingozzi and High 2013, Thomas et 
al. 2003). Non-viral vectors provide an alternative, but whilst these vectors are 
comparably safe, not immunogenic, low cost and easy to manufacture (Li and 
Huang, 2000, Wang et al. 2013), their transfection efficiency is often significantly 
reduced compared to their viral counterparts (He et al. 2010, Nayerossadat et al. 
2012). Physical enhancement techniques have also been used promote cell 
transfection. These include electroporation (Broderick et al. 2011, Drabick et al. 
2001, Guo et al. 2011, Roos et al. 2009), iontophoresis (Brand and Iversen, 1996, 
Vlassov et al. 1996), particle bombardment (Klein et al. 1987, Yang et al. 1990), 
tattooing (Bins et al. 2005, Oosterhuis et al. 2012), ultrasound (Newman and 
Bettinger, 2007) and radiofrequency ablation (Birchall et al. 2006). However these 
approaches are limited by the complexity and cost of the equipment, cell death and 
restricted access to the tissue or organ of interest (Meacham et al. 2014). The 
challenge of gene delivery at the cellular level is compounded in the skin, where a 
diverse range of cell populations exist in a complex three dimensional architecture. 
The most attractive target for localised gene expression in this stratified organ is the 
region with the greatest density of viable proliferating cells, i.e. the basal layer of the 
viable epidermis. This target layer exists 100 - 200 μm below the skin surface and is 
sandwiched by the terminally differentiating keratinocytes of the upper epidermis and 
the underlying connective tissue of the dermis. Potential targets for nucleic acid 
therapies also exist in the elastin and collagen packed layer of the dermis but cells in 
this region are not constrained to a membranous organisation and are often motile. 
Overcoming the physical and biological barriers of the skin, which has evolved to act 
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as a barrier to exogenous materials and insults, to target exogenous nucleic acids to 
specific cell types is therefore challenging. 
 
Despite these challenges, numerous studies have demonstrated that vectorless 
(naked) pDNA can transfect cells in both human and animal skin (Coulman et al. 
2006, Hengge et al. 1995, Hengee et al. 1996, Yan et al. 2014). This has been 
traditionally achieved via conventional intradermal injection, whereby a single 
hypodermic needle with millimetre dimensions is used to overcome the stratum 
corneum barrier and transfer a bolus of pDNA into the skin. However the resulting 
gene expression levels are low and often restricted to the viable epidermal cells that 
surround the injection site (Hengge et al. 1996) . This relatively inefficient method of 
delivery has therefore been augmented by physical transfection methods, such as 
electroporation (Broderick et al. 2011, Wells, 2004), which temporarily permeabilises 
cell membranes to enhance transfection levels in the tissue. Recent advances in this 
area, including Phase 2 clinical trial data (Trimble et al. 2015), are very encouraging. 
However conventional injections combined with electroporation have acknowleged 
limitations e.g. pain, bleeding and the inherent costs and complexity associated with 
electroporation technology. The ideal delivery system would therefore be a single 
and simple minimally invasive device (Miller and Pisani, 1999) that can achieve 
vectorless delivery of nucleic acids across both the tissue barrier, the stratum 
corneum, and the major cellular barrier, the cell membrane (Ibraheem et al. 2014).  
 
Microneedle (MN) technology uses single or multiple microscopic needles to deliver 
therapeutic materials through the stratum corneum (SC) barrier into the underlying 
viable epidermis, or dermis, in a minimally invasive manner. The primary advantage 
of MNs, compared to other ‘physical’ delivery methods, is the simplicity of the device.  
Studies have exemplified the potential of MNs for delivery of nucleic acids, both 
pDNA and siRNA, for the treatment of genetic skin diseases, cutaneous cancers, 
hyperproliferative diseases and vaccinations and these are summarised in a recent 
review (McCaffrey et al. 2015). These studies have employed solid MNs to deliver 
pDNA into the skin using either the “soak and poke” (Birchall et al. 2005, Coulman et 
al. 2006, Pearton et al. 2008, Yan et al. 2014) or the “coat and poke” approach 
(DeMuth et al. 2013, Gill et al. 2010, González-González et al. 2011, Kim et al. 2013, 
Pearton et al. 2012, Song et al. 2012). The former involves topical application of a 
liquid pDNA formulation prior to application of a MN device (Pearton et al. 2008). The 
“soak and poke” method results in reasonable levels of gene expression (Birchall et 
al. 2005, Chabri et al. 2004, Coulman et al. 2006, Pearton et al. 2008,  Yan et al. 
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2014) however it is impossible to control the delivered dose using this method. The 
alternative strategy is to “coat and poke” i.e. a MN device is dry coated with a pDNA 
formulation and then applied to the skin (DeMuth et al. 2013,  González-González et 
al. 2011, Pearton et al. 2012). MN coating methods are able to control the spatial 
distribution and mass of a therapeutic that is loaded onto MNs and thus dosing is 
more reproducible for the coat and poke approach (Kim et al. 2013). However the 
transfection efficiency of this method is significantly reduced (Pearton et al. 2012).  
Both of these approaches suffer from low to moderate levels of gene expression that 
are restricted to cells adjacent to the site of microdisruption. Transfection can be 
heightened by increasing tissue disruption using repeated MN applications to the 
skin surface (Yan et al. 2014) or lateral application of MNs (Mikszta et al. 2002). 
However, these approaches cause significant disruption of the tissue barrier that are 
unlikley to be clinically acceptable. 
 
The hollow MN approach administers the therapeutic cargo in a liquid formulation 
through one or more needles of micron dimensions. The advantages of hollow MN 
systems are conferred by its ability to inject a finite dose using a standard syringe 
and with minimal training. Re-formulation of commercially available medicines and 
vaccines is often not required and therefore the potential of hollow MNs has been 
established both pre-clinically and clinically (Daugimont et al. 2010, Gupta et al. 
2009, Gupta et al. 2012, Kim and Prausnitz, 2011, Levin et al. 2014, Levin et al. 
2015, Norman et al. 2013, Roxhed et al. 2008, Van Damme et al. 2009, Wang et al. 
2006). To the best of our knowledge, the ability of hollow MNs to deliver nucleic acids 
to human skin has not yet been reported. The aim of this study was to investigate the 
potential of a regulatory approved hollow MN device, MicronJet (Levin et al. 2015), 
for pDNA delivery to human skin in an effort to combine the favourable transfection 
efficiencies previously witnessed with liquid delivery (soak and poke approach) with 
the finite dosing that can be achieved using a hollow MN delivery system. 
 
 
2. Materials and methods 
All reagents and laboratory consumables were purchased from Fisher Scientific, UK, 
(Loughborough, UK), unless otherwise indicated. 
2.1 Ethics statement 
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Human skin samples were obtained from female patients undergoing breast 
reduction surgery or mastectomy under informed written patient consent and local 
ethical committee approval (South East Wales Research Ethics Committees Panel 
C, Reference: 08/WSE03/55). 
2.2 MN characterization 
The hollow MN devices (MicronJet) used in this study was provided by NanoPass 
Technologies Ltd. The device consists of an array of three MNs, each 600 μm in 
length, bonded to the tip of plastic adapter, which could be mounted on a standard 
hypodermic syringe. The needles were fabricated from silicon using MEMS (Micro 
Electro Mechanical Systems) technology (Van Damme et al. 2009). MicronJet MNs 
were visualised using a Stemi 2000-C Stereomicroscope (Zeiss, Welwyn Garden 
City, UK).  
2.3 Preparation of pDNA 
The reporter plasmids pCMVβ and pEGFP-N1 were amplified and purified from 
previously transformed stocks of DH5α Escherichia coli using antibiotic selective 
conditions and a Qiagen Mega Kit (Qiagen Ltd, Crawley, UK), (Birchall et al. 2005). 
The pIRES-TdTomato plasmid was obtained from Clontech. Plasmid propagation 
and purification was performed using a Qiagen Mega Kit  (pCMVβ and pEGFP-N1) 
or Qiagen HiSpeed Midi Kit (pIRES-TdTomato plasmid) (Qiagen Ltd, Crawley, UK). 
2.4 Collection, processing and maintenance of an ex vivo human skin 
Excised human breast skin was collected immediately after surgery and transported 
to the laboratory in culture media, which consisted of Dulbecco’s Modified Eagle 
Medium (DMEM), supplemented with 100 unit mL-1 of penicillin and 100 μg mL-1 of 
streptomycin (all Life Technologies, UK) at 4°C. Collected skin samples were used 
within 2 h of excision. Subcutaneous adipose tissue was removed by blunt dissection 
and skin was pinned, dermis side down, onto a cork dissection board to facilitate 
injection. An 8 mm biopsy punch was used to isolate areas of treated skin, which 
were further maintained in the organ culture by incubating at the air-liquid interface at 
37°C in an atmosphere of 5% (v/v) CO2/95% (v/v) air (Ng et al. 2009). Data in this 
study was obtained from replicate samples obtained from ten independent skin 
donors (aged 51- 80 years old). 
2.5 Gene expression in primary and continuous human keratinocyte cell lines 
2.5.1 HaCaT cell culture 
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Immortalised human keratinocyte cells (HaCaT cells), (Boukamp et al. 1988) were 
received as a gift from Professor Mark Gumbleton (School of Pharmacy and 
Pharmaceutical Sciences, Cardiff University). Cells were cultured in a growth 
medium, which consisted of DMEM, supplemented with 10% fetal bovine serum 
(FBS), 100 unit mL
-1
 of penicillin and 100 μg mL-1 of streptomycin (all Life 
Technologies, UK) at 37°C in a humidified atmosphere containing 5% CO2.   
2.5.2 Primary keratinocytes isolation and culture 
Superficial skin tissue was mechanically isolated from a full thickness skin sample 
using a surgical blade (approx. 1x1 cm2) and transferred to a 0.25% trypsin solution 
which was incubated overnight at 4°C. The resulting suspension of cells was filtered 
through a 70 μm cell strainer and centrifuged at 300 x g for 7 mins. The cell pellet 
was gently re-suspended in media (EpiLife medium supplemented with 10% human 
keratinocyte growth supplement (HGKS) and 100 unit mL-1 penicillin, 100 μg mL-1 of 
streptomycin and 2.5 μg mL-1 of amphotericin B (all Life Technologies, UK) before 
seeding in a 25cm2 flask. Growth media was changed every 2-3 days until the 
primary keratinocytes reached 70-80% confluence.  
2.5.3 HaCaT cell transfection 
Twenty four hours before treatment, cells were seeded into 24-well plates at a 
density of 7.5x104 cells cm-2 in 0.5 mL growth media. Cell populations were then 
treated using either (i) naked plasmid  (pEGFP-N1 or pIRES-TdTomato) or (ii) pDNA 
lipoplex formed with Lipofectamine2000 transfection reagent (positive control). 
Naked plasmid (0.6 μg in 100 μL PBS) was added to a well containing 500 μL of 
DMEM. Transfection complexes were prepared according to the manufacturer’s 
protocol (Life Technologies, UK). Briefly, 2 μL of Lipofectamine2000 was diluted in 50 
μL of DMEM and pDNA (0.6 μg /per well) was diluted in 50 μL of DMEM. After 5 min 
of incubation, pDNA and Lipofectamine2000 dilutions were mixed gently and allowed 
to equilibrate for 20 min at room temperature. Cells were washed once with PBS, 
and then lipoplexes (100 μL) were added to each well containing 500 μL of DMEM 
and mixed gently by rocking the plate back and forth. After 6 h, the cells were 
washed three times with PBS and the treatment media was replaced with DMEM 
supplemented with 10% FBS and the cells were incubated for a further 42 h. All 
experiments were performed at least in triplicate.  
2.5.4 Primary keratinocyte cell transfection  
Primary keratinocyte transfection was performed in a comparable manner to HaCaT 
transfection (Section 2.5.3), with the following exceptions. Twenty four hours before 
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treatment cells were seeded into 24-well plates at a density of 5x104 cells cm-2 in 0.5 
mL growth media. pDNA lipoplexes were prepared in EpiLife media and cells were 
treated as detailed in 2.5.3. After 6 h the treatment was removed and the cells were 
washed three times with PBS. EpiLife media, supplemented with 10% HGKS, was 
then added to the cell populations which were incubated for a further 42 h. All 
experiments were performed at least in triplicate.  
2.5.5 Examining gene expression in vitro 
Following a 42 h incubation period (Section 2.5.3 and 2.5.4), cell populations were 
washed three times with PBS before addition of EpiLife imaging media (Life 
Technologies, UK) to permit live cell imaging. The presence of GFP and TdTomato in 
cell monolayers was visualised using the Leica DM IRB epifluorescence microscope 
and imaging system (Leica Microsystems Ltd, UK). The transfection efficiency of 
pEGFP-N1 and pIRES-TdTomato was determined by flow cytometry using the 
FACSVerse flow cytometry system (BD Biosciences, UK). To prepare for FACS 
analysis cells were washed with PBS and then treated with trypsin-EDTA at 37°C for 
10 min. The cell suspension was then re-suspended in growth medium, centrifuged 
(Thermo Fisher Scientific, UK) at 300 × g for 5 min and washed with PBS. Pelleted 
cells were fixed with 100 μL of fixation buffer (BD Biosciences, UK) for 15 min at 4°C, 
washed and re-suspended in 200 μL of stain ing buffer (BSA), (BD Biosciences, UK) 
before flow cytometry analysis. GFP fluorescence was detected using a 527/32 filter, 
while TdTomato used a 568/42 filter (PE channel). On each sample, a minimum of 
10,000 events was collected. Analysis of collected data was performed with the 
FlowJo Flow Cytometry Analysis Software for Mac Version 10. (Tree Star Inc., USA). 
The percentage of gated cells in each sample indicates the percentage of fluorescent 
cells.  
2.6 MN mediated delivery of pDNA in vitro 
Twenty four hours before transfection HaCaT cells were seeded into 24-well plates at 
density of 7.5x105 cells cm-2 in 0.5 mL growth media. Cell populations were then 
treated using: (i) naked plasmid  (pEGFP-N1; 5 μg per well) injected into the media 
by pipette, (ii) naked plasmid (pEGFP-N1; 5 μg per well) injected into the media by 
MNs and (iii) pDNA lipoplex (pEGFP-N1; 5 μg per well) formed with 
Lipofectamine2000 transfection reagent (prepared according supplier’s 
recommended protocol) as a positive control. Transfection was performed using a 
comparable protocol to that described in Section 2.5.3. The transfection efficiency of 
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pEGFP-N1 in cells was determined by fluorescent microscopy and flow cytometry 
(Section 2.5.5). 
2.7 Gene expression in ex vivo human skin 
2.7.1 Conventional and MN injection of pDNA into human skin 
Following collection and preparation of excised skin (Section 2.4) 50 μL of pDNA 
(pCMVβ and pEGFP-N1) diluted in PBS, at a range of concentrations (detailed in 
results), was injected into the tissue using MicronJet MNs or a traditional hypodermic 
needle (BD Microlance 3, 26G x 3/8"). 50 μL of PBS was injected as a negative 
control. Following MN injection, the treatment sites were excised using 8 mm biopsy 
punches and incubated for 24 h at the air-liquid interface at 37°C and 5% (v/v) 
CO2/95% (v/v) air. Injections were performed at least in triplicate. 
2.7.2 Lateral MN disruption of human skin 
Split-thickness human skin was pinned onto a cork dissection board (Section 2.4). 20 
μl of  pDNA solution (pCMVβ) at concentration of 3.5 mg/ml was applied to the skin 
surface. A 4x4  array of MN-like structures, manufactured  using  silicon  wet etching 
techniques  (Wilke et al. 2005), was provided by the Tyndall National Institute. In this 
instance the wafer was removed from the etchant early in order to leave a flat 
uppermost surface, Figure 8D (insert), instead of the nm-sharp tip associated with 
conventional microneedles (O’Mahony, 2014). The flat tip of this truncated conical 
structure (more accurately termed a frustum tip) helps to enhance the skin disruption 
and maximise reliability when scraped laterally across the skin surface. This array 
was then applied in a downward motion to the edge of the treated area, under 
constant pressure, for a period of approximately 2 secs and subsequently moved 
laterally across the skin surface. 
2.7.3 Examination of plasmid expression in ex vivo human skin 
2.7.3.1 β-galactosidase enzyme detection 
Twenty four hours after treatment, all samples were rinsed in PBS for 30 min, and 
fixed in 2% glutaraldehyde/PBS at 4°C for 2 h. Subsequently, each sample was 
rinsed three times in PBS/ 4 mM MgCl
2 for 2 h. Samples were then immersed in X-
Gal staining solution (0.2% X-Gal, 2 mM MgCl2, 5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6 
prepared in PBS) for up to 16 h at 37°C. Following three times 30 minute PBS rinses 
the skin sample was visualised en face using a Stemi 2000-C Stereomicroscope 
(Zeiss, Welwyn Garden City, UK) and a KL1500 electronic external light source 
(Schott UK Limited, Stafford, UK), prior to each sample being embedded in OCT 
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medium and stored at -80°C. 
2.7.3.2 Preparation of skin cryosections and H&E staining 
Skin samples embedded in OCT blocks were sectioned using a Cryostat FSE 
(Thermo Scientific Shandon, UK). Skin sections (10 μm) were collected onto 
Superfrost Plus microscope slides and observed with an Olympus BX50 microscope 
(Olympus, Middlesex, UK). Selected slides were subsequently stained using 
haematoxylin and eosin (H&E) to visualize the skin architecture (Fischer et al. 2008). 
2.7.3.3 Intravital fluorescence imaging 
Skin treated with pEGFP-N1 plasmid was incubated for 24 h at 37°C, rinsed in PBS 
and fixed in 4% paraformaldehyde/PBS at 4°C for 24 h. Skin samples were then 
rinsed in PBS and imaged intravitally using the Kodak FX-Pro imaging system 
(Bruker Corporation), with wavelengths set to 470 nm (excitation) and 535 nm 
(emission). 
2.7.3.4 Fluorescence microscopy of skin sections 
Following 24 h incubation, skin samples were rinsed in PBS and fixed in 4% 
paraformaldehyde/PBS at 4°C for 24 h. Skin was then cryosectioned (2.7.3.2) and 
imaged using the Leica DM IRB epifluorescence microscope and imaging system 
(Leica Microsystems Ltd., UK). 
2.7.3.5 Preparation of epidermal sheets and fluorescent microscopy 
Skin treated with pEGFP-N1 was incubated for 24 h at 37°C before epidermal sheets 
were isolated by heat separation. Skin biopsy punches were incubated in water at 
60°C for 55 seconds after which the epidermis was removed from the dermis using 
forceps under a dissection microscope. Isolated epidermal sheets were then washed 
in PBS, fixed in acetone for 20 min at -20°C, washed again and mounted on slides 
using Dako fluorescent mounting medium (Dako, UK). The tissue was then 
visualised by a Leica DMI6000B confocal microscope (Leica Microsystems (UK) Ltd, 
UK) with LAS AF software (Leica Microsystems (UK) Ltd, UK). 
2.7.3.6 Fluorescence analysis of skin cells by flow cytometry  
Excised skin was maintained in organ culture for 24 h prior to removal of the lower 
dermis by blunt dissection (Ng et al. 2009). The remaining tissue was immersed in an 
enzyme solution containing Dispase II (2 units/ml) (Roche, UK), Collagenase I 
(197units/ml) and Deoxyribonuclease I (DNA-se I) from bovine pancreas (20 
units/ml) in RPMI 1640 (all Invitrogen, UK) for 1 h at 37°C. Epidermal sheets were 
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then mechanically separated from the dermis using forceps and placed in 0.25% 
(w/v) solution of trypsin for 30 min at 37°C. Following incubation, the epidermal 
sheets were pipetted up and down to increase cell yield and the suspension of the 
cells was passed through a 70 μm cell strainer. Single cell suspensions were 
subsequently centrifuged at 400 x g for 10 min and washed in PBS. Pelleted cells 
were fixed with 100 μL of fixation buffer (BD Biosciences, UK) for 15 min at 4°C, 
washed and re-suspended in 200 μL of stain buffer (BSA), (BD Biosciences, UK) 
before flow cytometry analysis (Section 2.5.5). 
2.8 Optical coherence tomography (OCT) of human skin following MN delivery 
Excised human skin was removed from -20°C storage and allowed to equilibrate to 
room temperature for approximately 2 h. Sub-cutaneous adipose tissue was 
removed by blunt dissection and skin was pinned, dermis side down, onto a cork 
dissection board to facilitate injection. Real time injections of methylene blue were 
visualised using the VivoSight System (Michelson Diagnostics, UK). The system is a 
Swept Source Fourier Domain OCT with clinical CE and FDA approval. This 
MultiBeam OCT system with <7.5 µm lateral resolution and <5 µm axial resolution in 
tissue is capable of achieving between 1.2 and 2.0 mm imaging depth and a 6×6 mm 
lateral field of view. Each OCT scan consists of 60 B-scans (in the x–y plane) with 4 
µm pixels, separated by 100 µm in the y direction. 
2.9 Data processing 
Image processing including scale bar inclusion was performed ImageJ software 
(National Institute of Health, USA). Statistical analysis of differences between 
transfection was determined by t-test analysis using GraphPad Prism software 
version 6.0c. 
 
 
3. Results 
3.1 Characterisation of MN devices 
MicronJet is a CE marked and FDA cleared device consisting of three MNs, each 
600 μm in length with a lumen that is approximately 60 μm in diameter, bonded to a 
plastic adapter that permits attachment to a Luer fit syringe (Fig 1). 
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Fig. 1.  
A hypodermic needle with intradermal-bevel (26-gauge) and Nanopass MicronJet 
600μm needles (brightfield microscopy).  
 
3.2 In vitro transfection of immortalised and primary keratinocytes 
Immortalised keratinocytes (HaCaT) were used to exemplify the functionality of the 
pEGFP-N1 and pIRES-TdTomato reporter plasmids. Freshly isolated human 
keratinocytes were subsequently used to determine transfection efficiency as these 
cells are more representative of the in vivo environment. A significant proportion 
(44.1 ± 0.2%) of HaCaT cells were positive for gene expression following treatment 
with the pEGFP-N1:Lipofectamine2000 lipoplex (Fig 2A). The detection of gene 
expression was reduced (10.1 ± 0.4%) in cells transfected with pIRES-
TdTomato:Lipofectamine2000 (Fig 2D). Gene expression efficiency in freshly 
isolated primary skin cells was reduced by an order of magnitude, with 3.8 ± 0.4% of 
the cell population transfected by pEGFP-N1 lipoplexes, and 0.8 ± 0.1% for pIRES-
TdTomato lipoplexes. Positive transfection by GFP and TdTomato was confirmed by 
fluorescence micrographs of HaCaT cells (Figure 2B and 2E) and primary 
keratinocytes (Figure 2C and 2F). 
1 mm 
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Fig. 2.  
Transfection efficiency of (A) pEGFP-N1 and (D) pIRES-TdTomato plasmid, as 
determined by flow cytometry of immortalised and primary human keratinocyte cell 
lines. Representative fluorescence micrographs of HaCaT (B, E) and primary 
keratinocyte human cell lines (C, F) treated with pEGFP-N1 (B, C) and pIRES-
TdTomato (E,F) lipoplexes with Lipofectamine2000 are also included to provide 
qualitative analysis. pDNA dose 0.6 μg in each treatment group. Statistical analysis: * 
p<0.05, **** p<0.0001. 
 
3.3 Evaluating MicronJet mediated delivery of plasmid DNA in human skin 
Experiments in viable human skin explants were performed to determine gene 
expression efficiency ex vivo following plasmid delivery via MicronJet MNs. Figure 3 
provides representative en face images of X-gal stained ex vivo human skin, 24 h 
after MicronJet delivery of the pCMVβ reporter plasmid (Figure 3B-3D and 3F-3H) or 
PBS as a control (Figure 3A and 3E). Histological sections indicate that MN 
penetration of human skin typically creates disruptions in human skin to a depth of 
200-250 μm and a width of 150 μm (Figure 3A). Gene expression, visualised as 
areas of punctate intense blue staining, is extensive with multiple sites of reporter 
protein staining (Figure 3B and 3C). Successful transfection was evident in at least 
three independent experiments in different skin donors and at all pCMVβ doses 
delivered (22.5 μg, 50 μg and 250 μg).  En face images and transverse sections 
(Figure  3B, 3C, 3F and 3G) suggest that gene expression occurs predominantly in 
the viable epidermis although gene expression can also been observed in the dermis 
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(Figure 3D, 3G and 3H). It is interesting to note that the site of gene expression was 
remote from the injection site (Figure 3B and 3C). Furthermore, whilst injection of 
naked plasmid DNA resulted in positive gene expression, injection of pCMVβ plasmid 
(22.5 μg) complexed with Lipofectamine 2000 did not result in detectable gene 
expression in ex vivo human skin (data not shown). 
 
Fig. 3.  
Images of ex vivo human skin following MicronJet 600µm injection of (A) PBS as a 
negative control or (B-H) naked pCMVß plasmid (250 μg in 50 μl), followed by 
incubation in X-gal solution. (A, B, C) provide en face images of the skin surface and 
(D) is the underside of a skin sample i.e. viewed from the dermis. Transverse 
cryosections (10µm) illustrate the (E) microneedle insertion site and successful 
transfection of pCMVß plasmid in the (F) epidermis, (G) epidermis and dermis and 
(H) dermis of the skin. Areas of transfection are highlighted by arrows. Donor skin in 
these exemplar images was obtained from 71 (A-C, E-H) and 54 years old females. 
 
Intravital imaging of human skin explants 24 h after MicronJet injection of naked 
pEGFP-N1 plasmid (300 μg) confirmed the results observed with pCMVβ, with the 
expressed GFP causing a significant increase in the fluorescence intensity for all four 
treated skin samples compared to the negative control. The pattern of localised 
expression also supports previous observations with pCMVβ, i.e. there is evidence of 
increased fluorescence distant from the injection site but within the confines of the 
raised bleb that is produced upon MicronJet injection of 50μl of pDNA solution 
(Figure 4B). Fluorescence imaging of epidermal sheets isolated from skin samples 
post-transfection validates the positive gene expression witnessed in intravital 
MN injection site 
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images (Figure 4C and 4D), whilst traditional histology methods confirm that gene 
expression occurs predominantly within the viable epidermis (Figure 4E and 4F). 
 
Fig. 4. 
Reporter gene expression in human skin tissue following MicronJet 600µm injection 
of naked pEGFP-N1. (A, B) Intravital images of four 8mm human skin biospy 
punches following injection of (A) PBS or (B) naked pEGFP-N1 plasmid (300 μg) 
using the MicronJet 600µm. Representative fluorescence micrographs showing 
positive gene expression in (C, D) human epidermal sheets treated with (C) 300 μg 
or (D) 50 μg of naked pEGFP-N1 plasmid. (E, F) are 10 μm cryosections of human 
skin following microneedle injection of 300 μg naked pEGFP-N1. Donor skin was 
obtained from 75 (A-B, E-F) and 60 years old females. 
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In a further experiment ex vivo human skin was treated with pEGFP-N1 delivered via 
MicronJet MNs 24 hours prior to epidermal cells being extracted from the tissue and 
analysed by fluorescence activated cell sorting (FACS). FACS plots indicate that a 
small population of the extracted epidermal cells were GFP positive (Figure 5B). 
Positive expression of the reporter protein in these skin-derived cells is further 
supported by fluorescence microscopy (Figure 5D). 
 
Fig. 5. 
Detectable GFP in epidermal cells that were isolated from freshly excised human 
skin following MicronJet 600 µm injection of naked pEGFP-N1 (250 μg). Control skin 
samples received an injection of PBS. Flow cytometry plots of (A) control epidermal 
cells and (B) epidermal cells transfected with pEGFP-N1 plasmid. Fluorescence 
micrographs of (C) a control epidermal cell suspension and (D) positive GFP 
expression within the epidermal cell suspension that has been isolated from human 
skin post-treatment. Donor skin was obtained from a 67 years old female. 
 
3.4 Understanding MicronJet-mediated delivery of plasmid DNA at the cellular level 
To determine the influence of the delivery method on transfection, pEGFP-N1 was 
delivered to a HaCaT cell monolayer either using a variable volume pipette or using 
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MicronJet MNs. Lipoplexes of pEGFP-N1 with Lipofectamine2000 (positive control) 
facilitated transfection of a significant proportion of cells (Fig 6B and 6D). Flow 
cytometry and fluorescence micrographs indicate that naked pEGFP-N1, delivered 
via MicronJet MNs (Figure 6C and 6E), can successfully transfect a small proportion 
of cells in vitro. However, this low level of gene expression was not observed when 
naked pEGFP-N1 was applied to the cell monolayer using a pipette (Figure 6A). 
 
Fig. 6. 
Representative flow cytometry plots and accompanying micrographs to illustrate 
pEGFP-N1 expression in HaCaT cells following treatment of the cell monolayer by 
different delivery strategies. Gene delivery was facilitated by (A) topical naked 
plasmid (5 μg) delivery from a pipette, (B, D) topical lipoplex (pEGFP-N1 plasmid 
with Lipofectamine2000) delivery from a pipette (positive control) or (C, E) naked 
plasmid (5 μg) extruded on to the cell monolayer through a MicronJet 600µm. 
 
3.5 Understanding MicronJet mediated delivery of plasmid DNA at the tissue level 
Optical coherence tomography (OCT) captured real time changes in the skin 
architecture during bleb formation by the MicronJet device. Localised disruption of 
the tissue at the point of injection was accompanied by adjacent distinct minor tissue 
disruptions, exclusive to the area of bleb formation (see Suppl. Figure 1A-C and 
Figure 7B and 7C). These microdisruptions appeared in a region of the tissue that is 
approximately 200-500μm below the skin surface and are a feature that were not 
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witnessed in untreated skin (Figure 7A) or during conventional intradermal injections 
(see Suppl. Figure 1A). Subsequent histological examination of the tissue following 
injection of pCMVβ supported OCT images, showing in some cases positive gene 
expression localised to areas of significant tissue disruption (Figure 7D, 7E and 7F). 
 
Fig. 7. 
(A, B,C) OCT images highlight (A) untreated and (B) microneedle treated ex vivo 
human skin, both (B) during and (C) after a 50μl microneedle injection of methylene 
blue using MicronJet 600µm needles. In (B) the microneedle can be identified 
adjacent to the bleb that is being created. The dashed orange line highlights the 
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border between the epidermal and dermal layers and the white dashed line in (C) 
indicates the edge of the bleb created by the microneedle injection. Arrows are used 
to highlight disruptions in the human skin architecture at positions that are distant 
from the microneedle insertion point, but within the confines of the bleb. Naked 
pCMV (250 μg in 50μl) was also injected into ex vivo human skin using the 
MicronJet 600µm and (D, E, F) light microscopy of 10 μm cryosections highlights 
pCMV expression proximal to mechanical disruptions (highlighted by a dashed blue 
line) in the skin tissue. Donor skin was obtained from 70 (A, B), 69 (C) and 71 
(D,E,F) year old females. 
 
Conventional intradermal injection of pCMVβ into ex vivo human skin resulted in 
gene expression in cells of the viable epidermis that are frequently adjacent to the 
point of injection (Figure 8B and 8C). Histological evaluation of the skin indicated that 
transfection is either associated with the epidermal cells that are proximal to the point 
of needle entry into the skin (the needle track, Figure 8E) or, if the tip of the needle 
was positioned in a cellular region, at the tip of the needle (both of these features 
were identified in a single sample in Figure 8F). Transfection following conventional 
intradermal injection of commensurate volumes of pCMVβ was therefore less 
extensive and significantly reduced compared to that observed with MicronJet 
injection. 
 
Fig. 8. 
En face images of ex vivo human skin treated with naked pCMVß plasmid and 
stained with X-gal solution. Skin samples were intradermally injected using a 
hypodermic needle to deliver (A) PBS (negative control), (B) 250µg of pCMVß in 50µl 
300 µm 500 µm 
10 µm 10 µm 10 µm 20 µm 
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or (C) 20µg of pCMVß in 20 µl into ex vivo skin tissue. (D) Alternatively the skin was 
treated by lateral application of a silicon microneedle array inset) following pre-
treatment of the skin with 70µg of a pCMV solution in 20µl. (E,F,G,H) Cryosections 
illustrate the location of transfection in the stratified tissue  following (E, F) 
intradermal injection or (G,H) lateral application of the silicon microneedle array. 
Donor skin was obtained from 71 (A, B), 51 (C, E, F) and 76 (D, G, H) year old 
females. 
 
To further explore the role of mechanical tissue disruption in mediating localised 
gene expression, silicon MN-like frustums were used to scarify the skin surface 
following topical liquid application of the pCMVβ plasmid. Lateral movement of the 
frustums across the skin surface resulted in multiple discrete areas of gene 
expression proximal to the mechanical microdisruptions (Figure 8D). Transverse 
sections confirmed plasmid expression in the viable epidermis and frustum induced 
mechanical microdisruptions in the upper layers of the tissue i.e. the epidermis and 
the papillary dermis (Figure 8G and 8H). 
 
 
 
 
 
4. Discussion 
There is a growing body of research that describes delivery of pDNA to murine (Gill 
et al. 2010, González-González et al. 2011, Kumar et al. 2012, Kim et al. 2014, Song 
et al. 2012) and other animal (DeMuth et al. 2013, Yan et al. 2014) models using 
solid MNs, particularly in the context of vaccination. Whilst these studies provide 
valuable information related to biological end-points and also exemplify the potential 
of solid MNs for pDNA delivery, the gross architecture and biology of animal and 
human skin have acknowledged differences, including the density, locations, 
proportions and phenotypes of both epidermal and dermal cells. Studies have also 
evaluated pDNA delivery in a viable ex vivo human skin model (Ng et al. 2009), but 
whilst studies have demonstrated proof-of-concept (Birchall et al. 2005, Coulman et 
al. 2006, Daugimont et al. 2010, McCaffrey et al. 2015, Pearton et al. 2012, Song et 
al. 2012), the ‘soak and poke’ and ‘coat and poke’ strategies are associated with 
limitations related to dosing reproducibility and transfection efficiency. 
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In this study hollow MNs (Figure 1) were used, for the first time, for the minimally 
invasive delivery of a pDNA solution into human skin. Experiments using two 
different reporter plasmids indicate that following MicroJet delivery of a known bolus 
dose of pDNA into human skin, transfection is more extensive and reproducible 
(Figure 3, 4) than that previously observed using the “soak and poke” (Birchall et al. 
2005, Coulman et al. 2006, Pearton et al. 2008, Yan et al. 2014) or “coat and poke” 
MN approaches (DeMuth et al. 2013, Gill et al. 2010, González-González et al. 2011, 
Kim et al. 2013, Pearton et al. 2012, Song et al. 2012). Most notably, the punctate 
areas of intense gene expression are remote from the injection site. This suggests 
that the MicronJet device facilitates transfection by a different mechanism than other 
published MN delivery strategies. A series of experiments were therefore conducted 
to elucidate the mechanism by which gene expression is enhanced upon MicronJet 
delivery of reporter pDNA to ex vivo human skin. 
 
Initial studies used a well-characterised immortalised human keratinocyte cell line 
(HaCaT cells) to exemplify the functionality of the reporter pDNA. Cell delivery using 
a commercial non-viral transfection reagent produced transfection rates of over 40% 
(Figure 2), however this did not translate to primary keratinocytes (Figure 2). The 
nuclear envelope is the major intracellular barrier to nuclear delivery of pDNA (Dean 
et al. 2005) and therefore transfection efficiencies are greatest in rapidly dividing 
cells, where the nuclear envelope is briefly but repeatedly compromised during 
mitosis (Escriou et al. 2001, Mortimer et al. 1999, Nicolau and Sene 1982, Wilke et 
al. 1996). Primary cells proliferate slowly and therefore transfection efficiencies in 
these cells are reduced. In terminally differentiating primary keratinocytes, where 
nuclear entry relies on passive translocation via the nuclear pore complex (Mattaj 
and Englmeier, 1998, Stoffler et al. 1999, Wilson et al. 1999), this problem is 
exacerbated. Therefore whilst immortalised keratinocytes and non-viral vectors are 
useful laboratory tools, the more representative primary keratinocyte cells used in 
this study exemplify the cellular barriers to transfection that exist in vivo. 
 
Treatment of the skin with a solid MN temporarily disrupts the stratum corneum and 
the plasma membranes of underlying viable cells. It has therefore been hypothesised 
that pre-treatment of the skin surface with a topical pDNA solution prior to application 
of a MN device (“soak and poke”) can facilitate almost simultaneous passage of 
pDNA across the skin barrier and into the cytoplasm of the cells in the viable 
epidermis (Pearton et al. 2012,  Yan et al. 2014). If the cell membrane recovers after 
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this mechanical trauma, and cell viability is maintained, intracellular delivery of pDNA 
will translate to expression of the exogenous gene product. The drawback of this 
mechanism of delivery is the exclusive proximity of positively-expressing cells to the 
MN insertions, which necessitates extensive or repeated MN applications to facilitate 
reasonable levels of gene expression. “Coat and poke” (Pearton et al. 2012) and 
“poke and soak” (Chabri et al. 2004, Mikszta et al. 2002, Pearton et al. 2008, Yan et 
al. 2014) strategies produce lower levels of gene expression due to the time delay 
between MN induced disruption of the cell membranes and exposure of the 
compromised cells to the pDNA. This delay is dependent on either the dissolution 
rate of the relatively insoluble macromolecular nucleic acid within the local 
environment of the skin tissue (“coat and poke”) or the interval between treatment of 
the skin with the MN device and topical application of a pDNA solution (“poke and 
soak”). Therefore a significant observable enhancement in both the level and 
distribution of gene expression following the use of hollow MNs, compared to their 
solid counterparts, suggests that this method of MN delivery improves cellular 
delivery as well as providing more reproducible and controlled dosing into the tissue. 
 
Delivery of a liquid bolus into human skin using a hollow MN may be considered to 
be more comparable to a conventional intradermal injection than solid MNs. 
However, the level and location of gene expression observed in ex vivo human skin 
following delivery of pDNA by hollow MNs is also significantly greater than that 
achieved using conventional intradermal injection (Figure 8B). Conventional 
intradermal injections use a 260μm needle bore and expel the liquid bolus in a single 
stream, compared to Micronjet, which uses three 60μm bores. The smaller bore sizes 
of the MicronJet increase the exit velocity of the liquid when a comparable downward 
pressure is applied to the syringe. The increased velocity is likely to facilitate greater 
direct cell transfection. In vitro experiments partially exemplified this point (Figure 6), 
with increased transfection evident when the naked pDNA was applied to cell 
monolayers using the MicronJet device compared to a pipette tip, although absolute 
gene expression levels remain low. Direct cell transfection by a high velocity liquid is 
also supported by a significant body of literature related to jet injections (Cartier et al. 
2000, Fargnoli et al. 2014, Fargnoli et al. 2016, Furth et al. 1995, Sawamura et al. 
1999, Walther et al. 2001, Walther et al. 2002). However, although a jet injection 
mechanism may contribute to the heightened gene expression observed in this 
study, the limited number of jets and the extensive distribution of gene expression 
suggest that it is unlikely to be the sole or major reason for the enhancement. 
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pDNA delivery using hollow MNs results in gene expression in cells remote from the 
point of injection, but which are restricted to the ‘bleb’ that is created by the 
intradermal liquid bolus (Figures 3 & 4). This ‘bleb’, as it is commonly referred to, is a 
discrete area of skin tissue that temporarily expands in response to the intradermal 
administration of a liquid volume. This type of event is also witnessed during the 
hydrodynamic delivery of nucleic acids to animal models (Liu et al. 1999, Zhang et al. 
1999, Bonamassa et al. 2011, Suda et al. 2007a), where a high speed and large 
volume tail vein injection of pDNA causes the liver to more than double in size (Suda 
et al. 2007b). Delivery of a large volume of liquid into the confined tissue space of the 
liver results in hydrostatic pressures that create temporary pores in the plasma 
membranes of cells, thus increasing permeability and heightening transfection. In 
animal models this facilitates gene expression in large numbers of cells in the liver 
and detectable levels of gene expression in other internal organs. This technique has 
also been transferred to animal skin, where rapid intradermal injection of a large 
volume (up to 100µl) of pDNA solution into a mouse foot pad facilitates significant 
gene expression (González-González et al. 2010). González-González et al. suggest 
that the presence of nucleic acid in the epidermis is not enough to facilitate 
keratinocyte uptake and propose that the hydrodynamic pressure created by 
intradermal injection of a relatively large volume of liquid into the confined space of 
the mouse foot pad causes transient membrane disruption of skin cells and facilitates 
cell uptake and subsequent plasmid expression. To date, hydrodynamic delivery has 
not been successfully used to facilitate transfection in human skin. 
 
In human skin conventional intradermal injection of a pDNA solution also results in 
observable expansion of the skin tissue. However there is limited gene expression 
and this is restricted to the point of injection and/or the needle track (Figure 8A-C; E-
F). The extent and pattern of transfection following conventional injection is therefore 
not characteristic of a hydrodynamic effect and is more likely caused by direct jet 
injection at the needle orifice and/or temporary mechanical damage to the cells at the 
point of needle insertion. The pressure created in the human tissue by conventional 
intradermal injection of 50 µl of a pDNA solution is therefore not great enough to 
facilitate extensive transfection in the cellular region of the skin. However delivery of 
the same injection volume (50 µl) containing the same reporter plasmid (pCMVB) to 
the same human skin model using the hollow MN device results in a significant 
enhancement to the level of exogenous gene expression (Figure 3). It is therefore 
the specific delivery system i.e. the hollow MN that is responsible for the increase in 
gene expression witnessed in this study. 
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Real time OCT videos and supportive microscopy images (Figure 7 & Suppl. Figure 
1A-C) indicate that hollow MN delivery of the liquid bolus is more superficial than that 
of conventional intradermal injection. This results in multiple microdisruptions to the 
skin architecture in the papillary dermis and at the epidermal-dermal junction (Figure 
7 and Suppl. Figurures 1A-C). These disruptions were created during the MN 
injection process (Figure 7B and Suppl. Figure 1B) but remain following completion 
of bolus delivery (Figure 7C and Suppl. Figure 1C). The disruptions were located at 
numerous points that are distant from the point of MN injection but within the 
confines of the bleb. Some of these changes were also co-localised with points of 
transfection (Figure 7D). These disruptions were not observed upon conventional 
intradermal injection (Figure 7A and Suppl. Figure 1A). We therefore postulate that, 
unlike conventional intradermal injections, hollow MNs are able to force large 
volumes of liquid (relative to the skin volume) at high speed (typically less than few 
seconds to administer 50 μl) into the papillary dermis, where elastin and collagen 
fibres are tightly packed and are in direct contact with the viable cells of the 
epidermal basement membrane. This creates hydrostatic pressures that physically 
disrupt the local tissue architecture and cause a transient increase in the permeability 
of cells in this region, which results in notable gene expression located exclusively 
with the skin ‘bleb’ (Figure 3 & 4). This proposed mechanism of transfection is akin to 
the hydrodynamic delivery witnessed in animal models, the main difference being 
that we have used a hollow MN device to replicate this in human skin tissue and 
have achieved it using relatively low injection volumes (50 μl). 
 
The pattern of gene expression following hollow MN mediated delivery of pDNA was 
not uniform. Discrete areas of gene expression were observed, predominantly in the 
viable epidermis but also in the dermis (Figure 3-5). The disparate pattern of gene 
expression is unsurprising given the proposed mechanism of transfection, i.e. 
hydrodynamic delivery is unlikely to create a uniform pattern of disruption in a 
heterogeneous tissue architecture. Indeed, OCT images and histology (Figure 7) 
support this, highlighting discrete areas of mechanical tissue disruption in the 
papillary dermis and epidermis, rather than uniform tissue disruption. Lateral 
application of a MN device (Mikszta et al. 2002) was used in the human skin model 
as an alternative method to create extensive superficial physical disruptions in the 
viable epidermis and papillary dermis (Figure 8 D, G-H). Delivery using this method 
also produced a random pattern of discrete areas of gene expression proximal to 
those points of mechanical disruption. Whilst lateral microneedle application is not 
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clinically useful, as it causes significant mechanical damage to the stratum corneum 
barrier, it provides an interesting comparator and supports the hypothesis that 
intradermal delivery of a pDNA solution through the MicronJet system also physically 
disrupts cell membranes in the papillary dermis and viable epidermis by a 
hydrodynamic effect, in this case without compromising the protective stratum 
corneum barrier. 
 
Transfection in the excised human tissue is therefore considerable following pDNA 
delivery by the MicronJet, but when skin cells are subsequently extracted from the 
bleb the relative number of transfected cells is low (Figure 5). This is likely a 
compound factor of the inherent difficulty in transfecting the dominant cell type of the 
epidermis i.e. primary terminally differentiating cells (Figure 2), restricted access of 
pDNA to all cells within the three dimensional skin architecture and, potentially, 
damage to transfected cells during extraction from the tissue. Successful transfection 
also relies on transient disruption of the plasma membrane, but in a proportion of 
cells the physical disruption is likely to be permanent and thus cause cell death. 
Therefore whilst the data provides an insight into the numbers of cells transfected it 
is likely to be an under-estimate of the transfection efficiency i.e. of the number of 
cells expressing the exogenous gene as a proportion of those cells that are able to 
be transfected. Additionally, levels of localised gene expression are significantly 
greater than that achieved by conventional intradermal injections or other MN 
delivery technologies and therefore may be suitable where high transfection 
efficiencies are not required e.g. nucleic acid vaccines or immunotherapy 
approaches. 
 
The observable enhancement in performance, compared to conventional intradermal 
injection and solid MNs, encourages development of hollow MN delivery systems for 
nucleic acid therapies. Whilst electroporation is now being investigated as an adjunct 
to enhance intracellular delivery of pDNA following the application of solid MNs (Wei 
et al. 2014), the hydrodynamic mechanism of cellular delivery associated with use of 
the hollow MN device may provide a simpler alternative. To the best of our 
knowledge, this is the first time that hydrodynamic gene delivery has been achieved 
in human skin and therefore further work is now required to optimise delivery and 
translate these results from reporter genes to therapeutically relevant pDNA. The 
extent and reproducibility of exogenous gene expression in human skin indicates that 
the CE marked MicronJet device may therefore provide a valuable platform for 
nucleic acid vaccination strategies or immunotherapy approaches. It is also important 
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to note that whilst multiple sub-surface microdisruptions created by the MicronJet in 
the skin are able to facilitate cellular uptake and subsequent expression of pDNA, 
there have been thousands of MicronJet injections with no reports of associated 
infection and therefore the enhancement in transfection is not at the expense of the 
minimally invasive principles of the MN delivery system.   
 
Conclusions 
This study exemplifies, for the first time, the use of hollow MNs for efficient vectorless 
delivery and expression of pDNA in human skin and proposes hydrodynamic delivery 
as the mechanism for enhanced gene expression, even with a ‘standard’ injection 
volume. Hydrodynamic gene delivery has not previously been observed in human 
skin tissue. The approved MicronJet hollow MN system ensures accurate delivery of 
a finite dose of exogenous DNA into the skin and provides more efficient and 
reproducible gene expression compared to solid MN delivery strategies. The delivery 
method provides potential advantages over other chemical and physical gene 
delivery methods with respect to cost, simplicity and flexibility of dosing and therefore 
could be the basis for future nucleic acid based immunotherapies and vaccines.  
Acknowledgements 
This work is part of the EE-ASI European research network (Collaborative Project) 
supported by the European Commission under the Health Cooperation Work 
Programme of the 7th Framework Programme (Grant agreement n° 305305). 
 
References 
A. Abdul-Wahab, W. Qasim, J.A. McGrath, Gene therapies for inherited skin 
disorders, Semin Cutan Med Surg. 33(2) (2014) 83-90. 
 
A.D. Bins, A. Jorritsma, M.C. Wolkers, C.F. Hung, T.C. Wu, T.N. Schumacher, J.B. 
Haaneen, A rapid and potent DNA vaccination strategy defined by in vivo monitoring 
of antigen expression, Nat Med 11 (2005) 899–904. 
 
J.C. Birchall, S.A. Coulman, M. Pearton, C. Allender, K. Brain, A. Anstey, C. Gateley, 
N. Wilke, A. Morrissey, Cutaneous DNA delivery and gene expression in ex vivo 
human skin explants via wet-etch microfabricated microneedles, J. Drug Target, 
13(7) (2005) 415–42. 
 
J.C. Birchall, S.A. Coulman, A. Anstey, C. Gateley, H. Sweetland, A. Gershonowitz, 
L. Neville, G. Levin, Cutaneous gene expression of plasmid DNA in excised human 
skin following delivery via microchannels created by radio frequency ablation, Int. J 
Pharm. 312 (1-2) (2006) 15-23. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 27 
 
B. Bonamassa, L. Hai, D. Liu, Hydrodynamic Gene Delivery and Its Applications in 
Pharmaceutical Research. Pharm Res 28(4) (2011) 694–701. 
 
P. Boukamp, R.T. Petrussevska, D. Breitkreutz, J. Hornung, A. Markham, N.E. 
Fusenig, Normal keratinization in a spontaneously immortalized aneuploid human 
keratinocyte cell line, J. Cell Biol. 106 (1988) 761–771. 
 
H. Boulaiz, J.A. Marchal, J. Prados, C. Melguizo, A. Aránega, Non-viral and viral 
vectors for gene therapy, Cell Mol Biol (Noisy-le-grand) 2(51) (2005) 3-22. 
 
R.M. Brand, P.L. Iversen, Iontophoretic delivery of atelomeric oligonucleotide, 
Pharm. Res. 13 (1996) 851–854. 
 
K.E. Broderick, X. Shen, J. Soderholm, F. Lin, J. McCoy, A.S. Khan, J. Yan, M.P. 
Morrow, A. Patel, G.P. Kobinger, S. Kemmerrer, D.B. Weiner, N.Y. Sardesai, 
Prototype development and preclinical immunogenicity analysis of a novel minimally 
invasive electroporation device, Mol Ther 3 (2011) 249–255. 
 
R. Cartier, S.V. Ren, W. Walther, U. Stein, A. Lewis, P.M. Schlag, M. Li, P.A. Furth, 
In vivo gene transfer by low-volume jet injection, Anal. Biochem. 282 (2000) 262-265. 
 
F. Chabri, K. Bouris, T. Jones, D. Barrow, A. Hanna, C. Allender, K. Brain, J. Birchall, 
Microfabricated silicon Microneedles for nonviral cutaneous gene delivery. Br. J. 
Dermatol. 150(5) (2004) 869–877. 
 
S.A. Coulman, D. Barrow, A. Anstey, C. Gateley, A. Morrissey, N. Wilke, C. Allender, 
K. Brain, J.C. Birchall, Minimally invasive cutaneous delivery of macromolecules and 
plasmid DNA via microneedles. Curr. Drug Deliv. 3(1) (2006) 65–75. 
 
L. Daugimont, N. Baron, G. Vandermeulen, N. Pavselj, D. Miklavcic, M-C. Jullien, G. 
Cabodevila L.M. Mir, V. reat, Hollow microneedle arrays for intradermal drug 
delivery and DNA electroporation, J. Membr. Biol. 236 (2010) 117–125. 
 
P.C. DeMuth, Y. Min, B. Huang, J.A. Kramer, A.D. Miller, D.H. Barouch, P.T. 
Hammond, D.J. Irvine, Polymer multilayer tattooing for enhanced DNA vaccination, 
Nat Mater. 12(4) (2013) 367-376. 
 
D.A. Dean, D.D. Strong, W.E. Zimmer, Nuclear entry of nonviral vectors, Gene Ther. 
12(11) (2005) 881-890. 
 
J.J. Drabick, J. Glasspool-Malone, A. King, R.W. Malone, Cutaneous transfection 
and immune responses to intradermal nucleic acid vaccination are significantly 
enhanced by in vivo electropermeabilization, Mol Ther 3 (2001) 249–255. 
 
V. Escriou, M. Carrière, F. Bussone, P. Wils, D. Scherman, Critical assessment of 
the nuclear import of plasmid during cationic lipid-mediated gene transfer, J Gene 
Med 3(2) (2001) 179-187. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 28 
 
A.S. Fargnoli, M.G. Katz, R.D. Williams, K.B. Margulies, C.R. Bridges, A Needleless 
Liquid Jet Injection Delivery Method for Cardiac Gene Therapy: A Comparative 
Evaluation Versus Standard Routes of Delivery Reveals Enhanced Therapeutic 
Retention and Cardiac Specific Gene Expression, J Cardiovasc Transl Res. 7(8) 
(2014) 756-767. 
 
A.S. Fargnoli, M.G. Katz, R.D. Williams, A.P. Kendle, N. Steuerwald, C.R. Bridges, 
Liquid jet delivery method featuring S100A1 gene therapy in the rodent model 
following acute myocardial infarction, Gene Ther. 23 (2016) 151-157. 
 
P.A. Furth, A. Shamay, L. Henninghausen, Gene transfer into mammalian cells by jet 
injection, Hybridoma, 14 (1995) 149–152. 
 
A.H. Fischer, K.A. Jacobson, J. Rose, R. Zeller, Haematoxylin and eosin staining of 
tissue and cell sections, CSH Protoc. 2008 pdb.prot4986. 
 
H.S. Gill, J. Soderholm, M.R. Prausnitz, M. Sallberg, Cutaneous vaccination using 
microneedles coated with hepatitis C DNA vaccine, Gene Ther. 17(6) (2010) 811-
814. 
 
E. González-González, H. Ra, R. Spitler, P. Hickerson, C.H. Contag, R.L. Kaspar, 
Increased interstitial pressure improves nucleic acid delivery to skin enabling a 
comparative analysis of constitutive promoters, Gene Ther. 17 (2010) 1270-1278. 
 
E. González-González, Y.C. Kim, T.J. Speaker, R.P. Hickerson, R. Spitler, J.C. 
Birchall, M.F. Lara, R.H. Hu, Y. Liang, N. Kirkiles-Smith, M.R. Prausnitz, L.M. 
Milstone, C.H. Contag, R.L. Kaspar, Visualization of plasmid delivery to keratinocytes 
in mouse and human epidermis, Sci Rep. 1 (2011) 158. 
 
S. Guo, A. Donate, G. Basu, C. Lundberg, L. Heller, R. Heller, Electro-gene transfer 
to skin using a noninvasive multielectrode array, J Control Release 151 (2011) 256–
262. 
 
J. Gupta, E.I. Felner, M.R. Prausnitz, Minimally invasive insulin delivery in subjects 
with type 1 diabetes using hollow microneedles, Diabetes Technol Ther. 11(6) (2009) 
329-337. 
 
J. Gupta, D.D. Denson, E.I. Felner, M.R. Prausnitz, Rapid local anesthesia in 
humans using minimally invasive MNs, Clin J Pain. 28(2) (2012) 129-135. 
 
I.R. Hart, R.G. Vile, Targeted therapy for malignant melanoma, Curr. Opin. Oncol. 6 
(1994) 221-225. 
 
C.H. He, Y. Tabata, J.Q. Gao, Non-viral gene delivery carrier and its three-
dimensional thansfection system, Int. J. Pharm. 386 (2010) 232-242. 
 
U.R. Hengge, E.F. Chan, R.A. Foster, P.S. Walker, J.C. Vogel, Cytokine gene 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 29 
expression in epidermis with biological effects following injection of naked DNA, Nat 
Genet 10 (1995) 161–166. 
 
U.R. Hengge, P.S. Walker, J.C. Vogel, Expression of naked DNA in human, pig, and 
mouse skin. J Clin Invest 97 (1996) 2911–2916. 
 
U.R. Hengge, W. Pfützner, M. Williams, M. Goos, J.C. Vogel, Efficient expression of 
naked plasmid DNA in mucosal epithelium: prospective for the treatment of skin 
lesions, J Invest Dermatol, 111 (1998) 605-608. 
 
J.L. Howarth, Y.B. Lee, J.B. Uney, Using viral vectors as gene transfer tools (Cell 
Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic 
manipulation of cells), Cell Biol Toxicol 26(1) (2010) 1–20. 
 
D. Ibraheem, A. Elaissari, H. Fessi, Gene therapy and DNA delivery systems, Int. J. 
Pharm. 459 (2014) 70-83. 
 
Y.C. Kim, M. Prausnitz, Enabling skin vaccination using new delivery technologies, 
Drug Deliv Trans Res. 1 (2011) 7–12. 
 
Y.C. Kim, D.G. Yoo, R.W. Compans, S.M. Kang, M.R. Prausnitz, Cross-protection by 
co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine 
using coated microneedles, J Control Release 172(2) (2013) 579-588. 
 
N.W. Kim, M.S. Lee, K.R. Kim, J.E. Lee, K. Lee, J.S. Park, Y. Matsumoto, D.G. Jo, 
H. Lee, D.S. Lee, J.H. Jeong, Polyplex-releasing microneedles for enhanced 
cutaneous delivery of DNA vaccine, J Control Release 10(179) (2014) 11-17. 
 
T.M. Klein, E.D. Wolf, R. Wu, J.C. Sanford, High-velocity microprojectiles for 
delivering nucleic acids into living cells, Nature 327 (1987) 70-73. 
 
A. Kumar, P. Wonganan, M.A. Sandoval, X. Li X, S. Zhu, Z. Cui, Microneedle-
mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA 
nanoparticles, J Control Release 28 (2012) 163(2):230-239. 
 
M.A. Kutzler, D.B. Weiner, DNA vaccines: ready for prime time? Nat. Rev. Genet 9 
(2008) 776-788. 
 
Y. Levin, E. Kochba, R. Kenney, Clinical evaluation of a novel microneedle device for 
intradermal delivery of an influenza vaccine: are all delivery methods the same? 
Vaccine 32(34) (2014) 4249-52. 
 
Y. Levin, E. Kochba, I. Hung, R. Kenney. Intradermal vaccination using the novel 
microneedle device MicronJet600: Past, present, and future. Hum Vaccin 
Immunother. 11(4) (2015) 991-997. 
 
S. Li, L. Huang, Nonviral gene therapy: promises and challenges, Gene Ther. 7(1) 
(2000) 31-34. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 30 
 
F. Liu, Y. Song, D. Liu, Hydrodynamics-based transfection in animals by systemic 
administration of plasmid DNA, Gene Ther. 6 (1999) 1258–1266. 
 
H. Lv, S. Zhang, B. Wang, S. Cui, J. Yan, Toxicity of cationic lipids and cationic 
polymers in gene delivery, J Control Rlease 114(1) (2006) 100-109. 
 
I.W. Mattaj, L. Englmeier, Nucleocytoplasmic transport: the soluble phase, Annu Rev 
Biochem 67 (1998) 265-306. 
 
J. McCaffrey, R.F. Donnelly, H.O. McCarthy, Microneedles: an innovative platform for 
gene delivery, Drug Deliv Transl Res. 5(4) (2015) 424-437. 
 
J.M. Meacham, K. Durvasula, F.L. Degertekin, A.G. Fedorov, Physical Methods for 
Intracellular Delivery: Practical Aspects from Laboratory Use to Industrial-Scale 
Processing, J Lab Autom. 19(1) (2014) 1-18. 
 
J.A. Mikszta, J.B. Alarcon, J.M. Brittingham, D.E. Sutter, R.J. Pettis, N.G. Harvey, 
Improved genetic immunization via micromechanical disruption of skin-barrier 
function and targeted epidermal delivery, Nat Med. 8(4) (2002) 415-419. 
 
M.A. Miller, E. Pisani, The cost of unsafe injections, Bull World Health Organ. 77(10) 
(1999) 808-811. 
 
F. Mingozzi, K.A. High, Immune responses to AAV vectors: overcoming barriers to 
successful gene therapy, Blood 122 (1) (2013) 23-36. 
 
I. Mortimer, P. Tam, I. MacLachlan, R.W. Graham, E.G. Saravolac, P.B. Joshia, 
Cationic lipid-mediated transfection of cells in culture requires mitotic activity, Gene 
Ther. 6(3) (1999) 403-411. 
 
N. Nayerossadat, T. Maedeh, P.A. Ali, Viral and nonviral delivery systems for gene 
delivery, Adv Biomed Res. 1 (2012) 27. 
 
C.M.H. Newman, T. Bettinger, Gene therapy progress and prospects: Ultrasound for 
gene transfer, Gene Therapy 14 (6) (2007) 465-475. 
 
K.W. Ng, M. Pearton, S. Coulman, A. Anstey, Ch. Gateley, A. Morrissey, Ch. 
Allender, J. Birchall, Development of an ex vivo human skin model for intradermal 
vaccination: tissue viability and Langerhans cell behavior, Vaccine 27(43) (2009) 
5948-5955. 
 
C. Nicolau, C. Sene, Liposome-mediated DNA transfer in eukaryotic cells. 
Dependence of the transfer efficiency upon the type of liposomes used and the host 
cell cycle stage, Biochim Biophys Acta 721(2) (1982) 185-190. 
 
J.J. Norman, S-O. Choi, N.T. Tong, A.R. Aiyar, S.R. Patel, M.R. Prausnitz, M.G. 
Allen, Hollow MNs for Intradermal Injection Fabricated by Sacrificial Micromolding 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 31 
and Selective Electrodeposition, Biomed Microdevices 15(2) (2013) 203–210. 
 
C. O’Mahony, Structural characterization and in-vivo reliability evaluation of silicon 
microneedles, Biomed. Microdevices 16(3) (2014) 333-343. 
 
K. Oosterhuis, J.H. van den Berg, T.N. Schumacher, J.B. Haanen, DNA vaccines 
and intradermal vaccination by DNA tattooing, Curr Top Microbiol Immunol 351 
(2012) 221–250. 
 
M. Pearton, C. Allender, K. Brain, A. Anstey, C. Gateley, N. Wilke, A. Morrissey, J. 
Birchall, Gene delivery to the epidermal cells of human skin explants using 
microfabricated microneedles and hydrogel formulations. Pharm. Res. 25 (2) (2008) 
407–416. 
 
M. Pearton, V. Saller, S.A. Coulman, C. Gateley, A.V. Anstey, V. Zarnitsyn, J.C. 
Birchall, Microneedle delivery of plasmid DNA to living human skin: formulation 
coating, skin insertion and gene expression. J. Controlled Release 160 (2012) 561–
569. 
 
H.L. Robinson, DNA vaccines: basic mechanism and immune responses (Review), 
Int J Mol Med. 4(5) (1999) 549-555. 
 
A.K. Roos, F. Eriksson, J.A. Timmons, J. Gerhardt, U. Nyman, L. Gudmundsdotter, 
A. Brave, B. Wahren, P. Pisa, Skin electroporation: effects on transgene expression, 
DNA persistence and local tissue environment, PLoS One 4(9) (2009) e7226. 
 
N. Roxhed, P. Griss, G. Stemme, Membrane-sealed hollow MNs and related 
administration schemes for transdermal drug delivery, Biomed Microdevices 10 
(2008) 271–279. 
 
D. Sawamura, S. Ina, K. Itai, X. Mex, A. Kon, K. Tamai, K. Hanada, I. Hashimoto, In 
vivo gene introduction into keratinocytes using jet injection, Gene Ther. 6 (1999) 
1785-1787. 
 
J.M. Song, Y.C. Kim, E.O.R.W. Compans, M.R. Prausnitz, S.M. Kang, DNA 
vaccination in the skin using miocroneedles improves protection against influenza, 
Mol Ther. 20(7) (2012) 1472-1480. 
 
D. Stoffler, B. Fahrenkrog, U. Aebi, The nuclear pore complex: from molecular 
architecture to functional dynamics, Curr Opin Cell Biol 11(3) (1999) 391-401. 
 
T. Suda, D. Liu, Hydrodynamic gene delivery: Its principles and applications, Mol. 
Ther. 15 (2007a) 2063–2069. 
 
T. Suda, X. Gao, D.B. Stolz, D. Liu, Structural impact of hydrodynamic injection on 
mouse liver, Gene Ther. 14 (2007b) 129–137. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 32 
C.E. Thomas, A. Ehrhardt, M.A. Kay, C.E. Thomas, Progress and problems with the 
use of viral vectors for gene therapy, Nat. Rev. Genet. 4(5) (2003) 346-358. 
 
C.L. Trimble, M.P. Morrow, K.A. Kraynyak, X. Shen, M. Dallas, J. Yan, L. Edwards, 
R.L. Parker, L. Denny, M. Giffear, A.S. Brown, K. Marcozzi-Pierce, D. Shah, A.M. 
Slager, A.J. Sylvester, A. Khan, K.E. Broderick, R.J. Juba, T.A. Herring, J. Boyer, J. 
Lee, N.Y. Sardesai, D.B. Weiner, M.L. Bagarazzi, Safety, efficacy, and 
immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human 
papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: 
a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386(1008) 
(2015) 2078-2088. 
 
P. Van Damme, F. Oosterhuis-Kafeja, M. Van der Wielen, Y. Almagor, O. Sharon, Y. 
Levin, Safety and efficacy of a novel MN device for dose sparing intradermal 
influenza vaccination in healthy adults, Vaccine 27(3) (2009) 454-459. 
 
V.V. Vlassov, M.V. Nechaeva, V.N. Karamyshev, L.A. Yakubov, Iontophoretic 
delivery of oligonucleotide derivatives into mouse tumor, Antisense Res. Dev. 4 
(1996) 291–293. 
 
W. Walther, U. Stein, I. Fichter, P.M. Schlag, In vivo gene transfer of naked DNA into 
xenotransplanted colon carcinoma by jet injection, Langenbeck’s Archives Surg. 30 
(2001) 69-72. 
 
W. Walther, U. Stein, I. Fichter, K. Voss, T. Schmidt, M. Schleef, T. Nellessen, P.M. 
Schlag, Intratumoral low volume jet injection for efficient nonviral gene transfer, Mol. 
Biotechnol. 21 (2002) 105-115.  
 
P.M. Wang, M. Cornwell, J. Hill, M.R. Prausnitz, Precise microinjection into skin 
using hollow microneedles, J Invest Dermatol. 126(5) (2006) 1080-1087. 
 
W. Wang, W. Li, N. Ma, G. Steinhoff, Non-viral gene delivery methods, Curr Pharm 
Biotechnol. 14(1) (2013) 46-60.  
 
Z. Wei, S. Zheng, R. Wang, X. Bu, H. Ma, Y. Wu, L. Zhu, Z. Hu, Z. Liang, Z. Li,  
A flexible microneedle array as low-voltage electroporation electrodes for in vivo 
DNA and siRNA delivery, Lab Chip. 14(20) (2014) 4093-4102. 
 
D.J. Wells, Gene Therapy Progress and Prospects: Electroporation and other 
physical methods, Gene Ther. 11 (2004) 1363-1369. 
 
M. Wilke, E. Fortunati, M. van der Broek, A.T. Hoogeveen, B.J. Scholte, Efficacy of a 
peptide-based gene delivery system depends on mitotic activity, Gene Ther. 3(12) 
(1996) 1133-1142.  
 
N. Wilke, A. Mulcahy, S.-R. Ye, A. Morrissey, Process optimization and 
characterization of silicon microneedles fabricated by wet etch technology, 
Microelectronics 36(7) (2005) 650-656.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 33 
 
G.L. Wilson, B.S. Dean, G. Wang, D.A. Dean, Nuclear import of plasmid DNA in 
digitonin-permeabilized cells requires both cytoplasmic factors and specific DNA 
sequences, J Biol Chem 274(31) (1999) 22025-22032. 
 
G. Yan, N. Arelly N, N. Farhan, S. Lobo, H. Li, Enhancing DNA delivery into the skin 
with a motorized microneedle device, Eur J Pharm Sci. 14(52) (2014) 215-222. 
 
N.S. Yang, J. Burkholder, B. Roberts, B. Martinell, D. McCabe, In vivo and in vitro 
gene transfer to mammalian somatic cells by particle bombardment, Proc Natl Acad 
Sci USA (1990). 
 
W.H. Yu, M. Kashani-Sabet, D. Liggitt, D. Moore, T.D. Heath, R.J. Debs, Topical 
gene delivery to murine skin, J Invest Dermatol 112 (1999) 370-375. 
 
G. Zhang, V. Budker, J.A. Wolff, High levels of foreign gene expression in 
hepatocytes after tail vein injections of naked plasmid DNA, Hum. Gene Ther. 10 
(1999) 1735–1737. 
 
 
 
 
Graphical abstract  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 34 
 
ACCEPTED MANUSCRIPT
